Improving Medication Adherence in Hypertensive Patients

Hypertension Clinical Trial

— HTNmobile  

Official title:

Improving Medication Adherence in Hypertensive Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01826435
• Other study ID #: Pro00043793
• Status: Withdrawn
• Phase: N/A
• First received: April 4, 2013
• Last updated: January 24, 2014
• Start date: January 2014
• Est. completion date: May 2015

Study information

• Verified date: January 2014
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The study team is proposing a single arm intervention to test the effect of an electronic intervention on medication use among individuals with a prescription for hypertension/high blood pressure. The investigator proposes that technology like text messaging, email, web applications and mobile apps with proven, nurse intervention scripts, will lead to significant, cost-effective improvements in hypertension medication use.

Description:

The intervention will incorporate a scalable electronic intervention using Email/Web Apps and Short Message Service (SMS)/Mobile Web Apps. The study team will examine the participants' responses to the electronic encounters in the technology-only intervention throughout the 3-month study timeframe.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2015
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Enrolled in the primary care clinic for the past 6 months

• New or existing prescription for hypertension

• Poorly controlled mean systolic blood pressure (SBP) in the last 12 months (>140/90 Hg)

Exclusion Criteria:

• Hospitalized for a stroke, myocardial infarction, coronary artery revascularization in the past 3 months,

• Diagnosis of metastatic cancer;

• Active diagnosis of psychosis or dementia documented in medical record;

• Does not have access to the appropriate technology required

• Is not willing to use said device to receive notifications for the study;

• Does not live independently (assisted living or nursing home residents) or otherwise institutionalized or receiving home health care

• Severely impaired hearing, vision or speech (unless technological aides allow them full functionality)

• Planning to leave the area or change primary care clinics prior to the anticipated end of participation;

• Unable to read and understand spoken English

• Participation in another cardiovascular disease (CVD) study

• Another household member enrolled in study;

• Arm size > 50cm

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Hypertension

Intervention

Behavioral:
• Electronic Intervention
Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.

Locations

Country	Name	City	State
United States	Duke University Health System Clinic	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of Days Covered (PDC)	Proportion of Days Covered (PDC), a Pharmacy Quality Alliance (PQA)-recommended metric for estimation of medication adherence for patients using chronic medications, will be used to identify the percentage of patients taking medications in a particular drug class with high adherence (PDC > 80% for the individual). Participants with a PDC =0.8 will be categorized as having "poor" adherence, and those with a PDC >0.8 will be categorized as having "good" adherence. For analyses, the PDC will be dichotomized at 0.8 (PDC >0.8) over the entire 3 month follow-up, yielding a single assessment of pill refill adherence that will be used as the primary outcome.	3 months	No